"Defending the inventor, armed with the patent shield,

under the banner of inventions promoting progress..."

versione italiana deutsch version


Modiano & Partners is one of the leading European firms specializing exclusively in intellectual property law, with a staff of over 250 persons and main offices in Munich (Germany), Milan (Italy), and Lugano (Switzerland).

We strive to offer the best possible service to all our clients and associates, and pride ourselves on our reputation of high quality, thoroughness, and long-standing expertise.

Our constant drive toward specialization has led us to expand our staff with intellectual property attorneys who are natives of, and qualified in, many different countries (in Europe, USA and Asia), creating an international team with several languages and experience of different legal traditions.

Our American patent attorneys were educated in the most prestigious US universities. Our German patent attorneys and lawyers have made valuable contributions to the firm and to the quality of service we give our clients. Our Italian attorneys have handled patent and trademark litigation, successfully defending industries and designers that are leading names in their fields. Our Swiss experts help us maintain a complete European overview of problems.

Drawing on the unique synergy of our European IP specialists, with their different legal traditions and their varied national experience, at Modiano & Partners we can offer our clients an in-depth and complete European counselling service.

  • Modiano & Partners was established in 1950, and from the start we have specialized in the international aspects of intellectual property law.

    Our founder, Dr. Guido Modiano, lived and studied in several European countries and in the US. His technical background and his vast knowledge of the legal aspects of the Italian, German and US legal systems enabled him to successfully focus on both international and European IP matters.

    More than anything else, it is the systematic passing on of this knowledge to all of Modiano’s attorneys that has been the determining factor in our growth.

  • For each case we choose the attorney (or attorney team) with the highest specialization in the area, the fastest turnaround and best effectiveness, as well as previous successful experience in similar cases. This policy usually translates to significant time and cost savings, to the client’s benefit.

    We are well aware of the our foreign associates’ and clients’ budget requirements, and this is why we always do our very best to meet such requirements and ensure that the associates and clients are notified immediately of any changes of circumstances which could influence the cost estimates indicated previously.

    All our departments have online subscriptions for consultation of the foremost databases on laws, case-law repertories, patents, trademarks etc., allowing extremely speedy search procedures. Our in-house libraries contain the most important intellectual property laws (European, US, Japanese, South Korean, Chinese etc.), as well as national and international treaties, reviews, journals and magazines.

July 28, 2021

当前, 全世界正在进行关于放弃C O V I D -19疫苗专权的讨论, 以加快疫苗供应, 尤其是针对那些受C O V I D -19病毒影响特别严重的国家. 欧洲议会 (European Parliament) 经过广泛讨论, 于2021年6月10日公布了一项决议. 在该决议中, […]

July 21, 2021
Double patenting: the European Patent Office issues a landmark decision.

The European Patent Convention (EPC) does not contain any specific provisions regarding the possibility for the same applicant to obtain […]

June 17, 2021
European Parliament issues resolution on waiver of patents on COVID-19 vaccines.

In the currently ongoing discussions about waiving patent rights for authorized COVID-19 vaccines in order to accelerate vaccine availability, particularly […]

May 19, 2021

欧洲专利局 (EPO) 的目标之一是支持整个欧洲的创新、竞争力和经济增长. 在COVID-19大流行期间, 这一目标变得比以往任何时候都更有意义. 欧洲专利局通过改进服务和增加程序期限的灵活性, 迅速对新的现状做出了反应. 欧洲专利局还制定了一系列其他措施, 以确保其业务的连续性以及对科学研究的支持;此外, 欧洲专利局还建立了最先进的专利信息和技术知识数据库, 以抗击病毒或治疗由其引起的其它疾病, 从而帮助世界各地的研究人员掌握最新发明. 某种程度上, 由于这些措施的帮助, 尽管发生了COVID-19大流行, 2020年, 向欧洲专利局提交的专利申请数量 (180250项) 和被授权的专利数量 (133715项) […]

Waiver of patents on COVID-19 vaccines: a European patent perspective.

Currently there is a great deal of discussion on the possibility of waiving the patent rights for authorized COVID-19 vaccines […]

April 28, 2021

在制药领域, 我们经常看到的情况是: 一旦 一种新的活性成分被发现并设计出第一个合适 的制剂, 随后的研究就会是对该活性成分的进一 步给药方案 (dosage regimen) 的开发, 以用于与 第一个制剂相关或不同的治疗适应症 (therapeutic indication). 因此, 给药方案是可以在欧洲专利局 (EPO) 获得专利授权的. 然而, 由于涉及经济利益, […]

How the EPO is helping its users during the COVID-19 pandemic.

One of goals of the European Patent Office (EPO) is to support innovation, competitiveness and economic growth across Europe. This […]

March 17, 2021
Pharmaceuticals and dosage regimen claims at the European Patent Office.

In the field of pharmaceuticals, it often happens that once an active ingredient is discovered and a first suitable formulation […]


2020年, 欧洲专利局 (EPO) 的上诉委员会 (BoA) 引入了新的议事规则. 上诉委员会强调, 上述规则的作用是对审查或异议中的一审程序进行司法审查. 新规则对在上诉中引入新证据、事实和论点的可能性进行了重大限制. 尽管如此, 上诉委员会于2020年12月7日发布的一项裁决认为, 上诉委员会具有否决一审程序中事实认定的权力. 上诉委员会在该决定中提到了其较早的一项决定. 根据该决定, 只有当欧洲专利局一审法庭对证据的评估存在以下缺陷之一时, 上诉委员会才应推翻该法庭在一审程序中作出的事实认定: (1) 没有考虑基本要点; (2) 审议不相关的事项; […]

February 23, 2021

欧洲专利局 (EPO) 正在密切关注人工智能 (Al) . 2020年12月, 欧洲专利局组织了一场为期2天的会议, 讨论了人工智能对知识产权的影响, 以及人工智能给欧洲专利局带来的益处. 这次会议反映出欧洲专利局正在对与人工智能有关的发明的可专利性问题进行重新定义. 欧洲专利局的立场是, 人工智能是计算机科学的一个分支. 因此, 根据欧洲专利局的做法, 与人工智能有关的发明被认为是“计算机实现的发明” (computer-implemented inventions, 简称CII) , 即涉及计算机、计算机网络或其他可编程装置的发明, […]

To use reCAPTCHA you must get an API key from https://www.google.com/recaptcha/admin/create